Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of Tiscover and AS210 in chronic (arterio-)venous leg ulcers
2010-021797-10Phase 2Terminated
- Sponsor
- VU university medical center
- Start
- Nov 2011
- Modality
- Cell Therapies, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of Tiscover in stasis ulcer and Mixed venous-arterial leg ulcer (MVALU) (2 arms), sponsored by VU university medical center. Primary endpoint: End of study outcome at 26 weeks. Started Nov 2011; status: terminated.
02
Drugs
Tiscover
03
Conditions
stasis ulcerMixed venous-arterial leg ulcer (MVALU)
Beyond the preview
Go deeper on 2010-021797-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021797-10.